Table 2.
Characteristics of patients and health controls included.
| Author | MM Ig Isotype | MM stage | Newly diagnosed or untreated | Cohort study | Gender (male, female) | Age (median, range) | ||
|---|---|---|---|---|---|---|---|---|
| MM | HC | MM | HC | |||||
| Li J (14) | IgG: 9, IgA: 7, Light chain only: 7 | D-S, I: 3; II 5; III: 15 | NA | NA | 16, 7 | 11, 7 | 66.5 (42–86) | 65.6 (53–79) |
| Gupta N (15) | NA | ISS, I: 4; II 14; III: 12 | YES | NA | 17,13 | 22, 8 | 59 (33-76) | 44 (33-55) |
| Shen X (16) | NA | NA | YES | YES | 13, 10 | NA | 62 (39-86) | 63 (40-76) |
| JIANG Y (17) | NA | D-S, I: 10; II 16; III: 19 | YES | NA | 23, 12 | 8, 12 | 59 (35-75) | (17-63) |
| Qu X (18) | IgG: 18, IgA: 10, IgD: 1, Light chain only: 10, non-secretory: 1 | ISS, I: 7; II: 13; III: 20 | YES | NA | 23, 17 | 10, 10 | 59 (23-80) | 60 (35-75) |
| Kubiczkova L (19) | IgG: 54, IgA: 28, IgD: 3, IgM: 2,Light chain only: 11 | ISS, I: 35; II: 29; III: 39 | YES | YES | 51, 52 | 14, 16 | 66 (47-83) | 55 (45-64) |
| Yoshizawa S (20) | IgG: 26, IgA: 12, IgD:3, B-J protein: 14, non-secretory: 4; plasma cell leukemia: 3 | NA | YES | NA | NA | NA | NA | NA |
| Jones Cl (21) | NA | NA | NA | NA | 12, 12 | 5, 8 | 73.5 (58-89) | 47.7 (42-58) |
| Hao M (22) | IgG: 51, IgA: 29, IgD: 8, Light chain only: 18, non-secretory: 2 | ISS, I: 18; II: 39; III: 50, not classified: 1. | YES | YES | NA | NA | (33-83) | 52 (40-78) |
| Y u J (13) | IgG: 22, IgA: 13, IgD: 5 | NA | NA | NA | 25, 15 | 18, 12 | 62 (35-87) | 63 (40-86) |
| Sevcikova S (23) | IgG: 46, IgA: 22, IgD: 2 Light chain only: 16, non-secretory: 2, Biclonal:1 | ISS, I: 28; II: 32; III: 26, not classified: 5. | YES | YES | 49, 42 | 14, 16 | 63.9 (41-48) | 55.5 (45-64) |
D-S, Durie-salmon stage; HC, health control; ISS: International Staging System stage; MM, multiple myeloma; NA, not available.